Cargando…

Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial

We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase III trial. Acceptability measures were captured using ACASI at month 3 and end of product use (median 24 months, IQR 15–30). Mont...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayo, Ashley J., Browne, Erica N., Montgomery, Elizabeth T., Torjesen, Kristine, Palanee-Phillips, Thesla, Jeenarain, Nitesha, Seyama, Linly, Woeber, Kubashni, Harkoo, Ishana, Reddy, Krishnaveni, Tembo, Tchangani, Mutero, Prisca, Tauya, Thelma, Chitukuta, Miria, Gati Mirembe, Brenda, Soto-Torres, Lydia, Brown, Elizabeth R., Baeten, Jared M., van der Straten, Ariane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222015/
https://www.ncbi.nlm.nih.gov/pubmed/33713213
http://dx.doi.org/10.1007/s10461-021-03205-z
_version_ 1783711422491918336
author Mayo, Ashley J.
Browne, Erica N.
Montgomery, Elizabeth T.
Torjesen, Kristine
Palanee-Phillips, Thesla
Jeenarain, Nitesha
Seyama, Linly
Woeber, Kubashni
Harkoo, Ishana
Reddy, Krishnaveni
Tembo, Tchangani
Mutero, Prisca
Tauya, Thelma
Chitukuta, Miria
Gati Mirembe, Brenda
Soto-Torres, Lydia
Brown, Elizabeth R.
Baeten, Jared M.
van der Straten, Ariane
author_facet Mayo, Ashley J.
Browne, Erica N.
Montgomery, Elizabeth T.
Torjesen, Kristine
Palanee-Phillips, Thesla
Jeenarain, Nitesha
Seyama, Linly
Woeber, Kubashni
Harkoo, Ishana
Reddy, Krishnaveni
Tembo, Tchangani
Mutero, Prisca
Tauya, Thelma
Chitukuta, Miria
Gati Mirembe, Brenda
Soto-Torres, Lydia
Brown, Elizabeth R.
Baeten, Jared M.
van der Straten, Ariane
author_sort Mayo, Ashley J.
collection PubMed
description We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase III trial. Acceptability measures were captured using ACASI at month 3 and end of product use (median 24 months, IQR 15–30). Monthly returned rings were classified as nonadherent if dapivirine release rate was ≤ 0.9 mg/month. Associations between acceptability measures and nonadherence were estimated using Poisson regression models with robust standard errors. At month 3 (N = 2334), 88% reported DVR was comfortable, 80% were unaware of it during daily activities, and 74% never felt it during sex. At exit, 66% were ‘very likely’ to use DVR in the future. Acceptability was found to differ significantly by country across several measures including wearing the ring during sex, during menses, partner acceptability, impact on sexual pleasure and willingness to use the ring in the future. Risk of nonadherence at month 12 was elevated if DVR was felt during sex at month 3 (aRR 1.67, 95% CI 1.26, 2.23). Risk of nonadherence in the last year of study participation was elevated if, at exit, participants minded wearing during sex (aRR 2.08, 95% CI 1.52, 2.85), during menses (aRR 1.57, 95% CI 1.06, 2.32), reported a problematic change to the vaginal environment (aRR 1.57, 95% CI 1.12, 2.21), and were not “very likely” to use DVR in the future (aRR 1.31, 95% CI 1.02, 1.68). DVR acceptability was overall high yet varied by country. Addressing perceived ring interference with sex, menses, or problematic changes to the vaginal environment in future interventions could help improve adherence, as could embracing sex-positive messaging related to ring use and increased pleasure. Trial Registration ClinicalTrials.gov Identifier: NCT01617096. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10461-021-03205-z.
format Online
Article
Text
id pubmed-8222015
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-82220152021-06-28 Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial Mayo, Ashley J. Browne, Erica N. Montgomery, Elizabeth T. Torjesen, Kristine Palanee-Phillips, Thesla Jeenarain, Nitesha Seyama, Linly Woeber, Kubashni Harkoo, Ishana Reddy, Krishnaveni Tembo, Tchangani Mutero, Prisca Tauya, Thelma Chitukuta, Miria Gati Mirembe, Brenda Soto-Torres, Lydia Brown, Elizabeth R. Baeten, Jared M. van der Straten, Ariane AIDS Behav Original Paper We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase III trial. Acceptability measures were captured using ACASI at month 3 and end of product use (median 24 months, IQR 15–30). Monthly returned rings were classified as nonadherent if dapivirine release rate was ≤ 0.9 mg/month. Associations between acceptability measures and nonadherence were estimated using Poisson regression models with robust standard errors. At month 3 (N = 2334), 88% reported DVR was comfortable, 80% were unaware of it during daily activities, and 74% never felt it during sex. At exit, 66% were ‘very likely’ to use DVR in the future. Acceptability was found to differ significantly by country across several measures including wearing the ring during sex, during menses, partner acceptability, impact on sexual pleasure and willingness to use the ring in the future. Risk of nonadherence at month 12 was elevated if DVR was felt during sex at month 3 (aRR 1.67, 95% CI 1.26, 2.23). Risk of nonadherence in the last year of study participation was elevated if, at exit, participants minded wearing during sex (aRR 2.08, 95% CI 1.52, 2.85), during menses (aRR 1.57, 95% CI 1.06, 2.32), reported a problematic change to the vaginal environment (aRR 1.57, 95% CI 1.12, 2.21), and were not “very likely” to use DVR in the future (aRR 1.31, 95% CI 1.02, 1.68). DVR acceptability was overall high yet varied by country. Addressing perceived ring interference with sex, menses, or problematic changes to the vaginal environment in future interventions could help improve adherence, as could embracing sex-positive messaging related to ring use and increased pleasure. Trial Registration ClinicalTrials.gov Identifier: NCT01617096. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10461-021-03205-z. Springer US 2021-03-13 2021 /pmc/articles/PMC8222015/ /pubmed/33713213 http://dx.doi.org/10.1007/s10461-021-03205-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Mayo, Ashley J.
Browne, Erica N.
Montgomery, Elizabeth T.
Torjesen, Kristine
Palanee-Phillips, Thesla
Jeenarain, Nitesha
Seyama, Linly
Woeber, Kubashni
Harkoo, Ishana
Reddy, Krishnaveni
Tembo, Tchangani
Mutero, Prisca
Tauya, Thelma
Chitukuta, Miria
Gati Mirembe, Brenda
Soto-Torres, Lydia
Brown, Elizabeth R.
Baeten, Jared M.
van der Straten, Ariane
Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
title Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
title_full Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
title_fullStr Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
title_full_unstemmed Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
title_short Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
title_sort acceptability of the dapivirine vaginal ring for hiv-1 prevention and association with adherence in a phase iii trial
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222015/
https://www.ncbi.nlm.nih.gov/pubmed/33713213
http://dx.doi.org/10.1007/s10461-021-03205-z
work_keys_str_mv AT mayoashleyj acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT browneerican acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT montgomeryelizabetht acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT torjesenkristine acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT palaneephillipsthesla acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT jeenarainnitesha acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT seyamalinly acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT woeberkubashni acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT harkooishana acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT reddykrishnaveni acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT tembotchangani acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT muteroprisca acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT tauyathelma acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT chitukutamiria acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT gatimirembebrenda acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT sototorreslydia acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT brownelizabethr acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT baetenjaredm acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT vanderstratenariane acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial
AT acceptabilityofthedapivirinevaginalringforhiv1preventionandassociationwithadherenceinaphaseiiitrial